News + Filings Transactions Holdings
All
13F
13D/G
Other
|
|
Tarriff Scott
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Sold 9,511 shares
@ $15.23, valued at
$144.9k
Sold 10,024 shares
@ $14.41, valued at
$144.4k
Sold 710 shares
@ $15.11, valued at
$10.7k
|
|
| 05/18/2023 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Sold 15,000 shares
@ $19.98, valued at
$299.7k
|
|
| 05/15/2023 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Sold 15,000 shares
@ $20.71, valued at
$310.7k
Sold 3,131 shares
@ $19.69, valued at
$61.6k
Sold 11,869 shares
@ $20.42, valued at
$242.4k
Sold 14,800 shares
@ $21.06, valued at
$311.7k
Sold 200 shares
@ $21.52, valued at
$4.3k
|
|
| 03/02/2023 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 3,113 shares
@ $28, valued at
$87.2k
Granted 70,900 shares
@ $0 |
|
| 01/24/2023 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 3,732 shares
@ $33.64, valued at
$125.5k
|
|
| 01/09/2023 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 3,827 shares
@ $29.26, valued at
$112k
|
|
| 03/02/2022 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 34,800 shares
@ $0 |
|
| 04/05/2021 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Gifted 16,340 shares
@ $0
Paid exercise price by delivering 16,278 shares
@ $41.87, valued at
$681.6k
Exercised 31,201 options to buy
@ $8.78, valued at
$273.9k
|
|
| 01/26/2021 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 4,631 shares
@ $47.7, valued at
$220.9k
|
|
| 11/12/2020 |
4
| Tarriff Scott (Former Director) has filed a Form 4 on Synthetic Biologics, Inc. |
| 01/27/2020 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 7,548 shares
@ $57.98, valued at
$437.6k
|
|
| 01/07/2020 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 58,300 shares
@ $0
Granted 145,700 options to buy
@ $59.795, valued at
$8.7M
|
|
| 01/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/06/2019 |
4
| Tarriff Scott (Director) has filed a Form 4 on Synthetic Biologics, Inc.|
Txns:
| Granted 250,000 options
@ $0.418, valued at
$104.5k
|
|
| 04/03/2019 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Sold 24,975 shares
@ $50.15, valued at
$1.3M
|
|
| 03/04/2019 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Sold 12,000 shares
@ $50.51, valued at
$606.1k
Sold 12,428 shares
@ $51.81, valued at
$643.9k
|
|
| 02/04/2019 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Sold 29,185 shares
@ $41.52, valued at
$1.2M
Sold 900 shares
@ $42.3, valued at
$38.1k
|
|
| 01/25/2019 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 61,300 shares
@ $0
Granted 137,200 options to buy
@ $42.4, valued at
$5.8M
|
|
| 01/04/2019 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Sold 6,500 shares
@ $39.3, valued at
$255.5k
Sold 8,500 shares
@ $40.03, valued at
$340.3k
Sold 10,597 shares
@ $39.04, valued at
$413.7k
Sold 5,670 shares
@ $39.7, valued at
$225.1k
Sold 302 shares
@ $40.57, valued at
$12.3k
|
|
| 01/02/2019 |
4
| Tarriff Scott (Director) has filed a Form 4 on ZIOPHARM ONCOLOGY INC|
Txns:
| Granted 126,700 options to buy
@ $1.87, valued at
$236.9k
|
|
| 12/07/2018 |
4
| Tarriff Scott (Director) has filed a Form 4 on Synthetic Biologics, Inc.|
Txns:
| Granted 79,500 options
@ $0.6895, valued at
$54.8k
|
|
| 07/03/2018 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Exercised 124,804 options to buy
@ $4.04, valued at
$504.2k
|
|
| 04/03/2018 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 57,895 shares
@ $52.69, valued at
$3.1M
Exercised 113,104 options to buy
@ $4.04, valued at
$456.9k
|
|
| 01/09/2018 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Granted 157,000 options to buy
@ $59.14, valued at
$9.3M
Granted 189,000 options to buy
@ $0 |
|
| 01/03/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/21/2017 |
4
| Tarriff Scott (Director) has filed a Form 4 on Synthetic Biologics, Inc.|
Txns:
| Granted 200,000 options
@ $0.52, valued at
$104k
|
|
| 01/06/2017 |
4
| Tarriff Scott (CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC. |
| 01/04/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 12/02/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 11/18/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 04/05/2016 |
4
| Tarriff Scott (President and CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Sold 30,765 shares
@ $40.63, valued at
$1.2M
|
|
| 03/03/2016 |
4
| Tarriff Scott (President and CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Sold 7,802 shares
@ $62.7, valued at
$489.2k
Sold 11,978 shares
@ $63.52, valued at
$760.8k
|
|
| 02/02/2016 |
4
| Tarriff Scott (President and CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Sold 5,367 shares
@ $66.03, valued at
$354.4k
Sold 3,600 shares
@ $67.46, valued at
$242.9k
Sold 5,260 shares
@ $68.52, valued at
$360.4k
Sold 2,431 shares
@ $69.95, valued at
$170k
Sold 1,702 shares
@ $71.84, valued at
$122.3k
|
|
| 01/05/2016 |
4
| Tarriff Scott (President and CEO) has filed a Form 4 on EAGLE PHARMACEUTICALS, INC.|
Txns:
| Sold 11,776 shares
@ $85.65, valued at
$1M
Sold 2,773 shares
@ $87.02, valued at
$241.3k
Granted 180,000 options to buy
@ $86.15, valued at
$15.5M
|
|
|
|
|